Organigram Is A Small-Cap Bargain
Organigram's balance sheet is robust with C$46.8 million in cash, no debt, and a healthy current ratio. See why I rate OGI ...
Innoviva: Underappreciated Strength In Hospital Therapeutics
Innoviva's shift to specialty therapeutics is backed by strong financials and a robust pipeline. Read why INVA stock presents ...